Fabry Disease: Causes, Symptoms, Complications, and Treatment

What is Fabry Disease?

Fabry disease (also known as alpha-galactosidase-A deficiency) is an inherited lysosomal storage disorder that occurs when the enzyme alpha-galactosidase-A is unable to efficiently break down certain fats. This genetic defect causes a progressive and dangerous accumulation of fatty substances, primarily a lipid called globotriaosylceramide (Gb3), throughout the body. This accumulation particularly affects the autonomic nervous system (the part of the nervous system that controls involuntary functions such as breathing and heartbeat), as well as the eyes, kidneys, and cardiovascular system.

Males are more severely affected, though a milder form can also be observed in females. Symptoms typically begin during childhood or adolescence, with characteristic neurological signs that include:

• Burning pain in the arms and legs, worsening with heat or after physical exercise.
• Corneal deposits: Accumulation of excess material in the superficial layers of the cornea, which can cause blurred vision.
• Altered circulation, which can promote the development of stroke and heart attack due to fat buildup in the walls of blood vessels

Other symptoms include:

• Pathological enlargement of the heart
• Progressive kidney failure
• Gastrointestinal disturbances
• Reduced sweating (anhidrosis or hypohidrosis)
• Fever episodes
• Angiokeratomas: Small, raised, non-cancerous spots on the skin. These spots are usually red to violet in color and often appear in the lower trunk area. Their number tends to increase with age.

Treatment includes enzyme replacement therapy (ERT) to supply the missing enzyme, reducing lipid accumulation, relieving pain, and preserving organ function. Additional medications may be prescribed to manage pain, gastrointestinal discomfort, and to prevent cardiovascular events through antiplatelet or anticoagulant agents.

---

Causes

Fabry disease is an inherited condition arising from “the accumulation of fat (particularly in the form of globotriaosylceramide) in visceral tissues and the vascular endothelium throughout the body, causing damage to the kidneys, heart, and central nervous system that compromises quality of life and life expectancy”.

It affects approximately 1 in 1,000 to 1 in 9,000 individuals, and milder, late-onset forms appear to be more common than the classic severe presentation.

The Genetic Defect

Fabry disease is caused by mutations in the GLA gene, which provides instructions for producing the enzyme alpha-galactosidase A. This enzyme is active in the lysosomes, which are cellular organelles that act as recycling centers, and it is responsible for breaking down the fatty substance globotriaosylceramide (Gb3).

Defective variants of the GLA gene alter the structure and function of the enzyme, impairing its ability to effectively break down Gb3. As a result, globotriaosylceramide builds up to dangerous levels in cells throughout the body. This accumulation is especially severe in the cells lining blood vessel walls and in the cells of the kidneys, heart, and nervous system. This progressive accumulation damages cells and produces the diverse signs and symptoms of Fabry disease.

• Mutations causing complete enzyme inactivity are responsible for the classic severe form of the disease
• Mutations that reduce but do not eliminate enzyme activity typically cause milder, late-onset forms, which generally affect only the heart, kidneys, or cerebral blood vessels

Inheritance

Fabry disease is transmitted in an X-linked pattern. This means the defective gene is located on the X chromosome, one of the two sex chromosomes present in each cell.

• Males (who have only one X chromosome) need only one altered copy of the GLA gene to develop the condition; they are therefore more severely affected.
• Females (who have two X chromosomes) carry one altered and one normal copy of the GLA gene. In many cases, the second healthy chromosome provides partial compensation. This often leads to milder symptoms or, occasionally, no symptoms at all.

However, unlike many other X-linked conditions, Fabry disease causes significant complications in many women even with only one altered GLA gene copy. These women can develop many of the classic features of the disorder, including:

• Nervous system abnormalities
• Kidney problems
• Chronic pain and fatigue
• Increased risk of high blood pressure
• Heart disease, stroke, and kidney failure

This means that no woman who carries a GLA mutation should be dismissed as merely a carrier. Instead, thorough clinical evaluation and monitoring are essential for all individuals, regardless of sex.

---

Symptoms

Symptoms in Males

Males may begin to experience the first signs of Fabry disease in childhood or early adolescence. Almost all organ systems can potentially be involved. The most common early symptoms include:

• Acroparesthesias: painful burning, numbness, and tingling in the fingers and toes.
• Reduced sweating (hypohidrosis or anhidrosis) and reduced tear production
• Gastrointestinal symptoms, particularly abdominal cramps and diarrhea.
• Skin manifestations:
  • Small petechiae (bruise-like spots) around the navel
  • Angiokeratomas: raised red, violet, or bluish papules. These lesions often appear in the “bathing suit” area.
• Eye and vision disturbances, including corneal clouding (cornea verticillata). This condition is visible on slit-lamp examination but typically does not affect vision.

Additional Symptoms

Other symptoms that may be associated with Fabry disease include:

• Chronic fatigue and exhaustion
• Dizziness and vertigo
• Headaches
• Generalised weakness
• Nausea and/or vomiting
• Delayed puberty and reduced body hair growth
• Enlarged lymph nodes
• Intolerance to heat, cold, or intense physical exercise

Symptoms in Females

Signs and symptoms of Fabry disease generally appear later in life and are milder in females. In a small percentage of cases, the condition is entirely asymptomatic. However, as noted above, many women do develop serious complications over time.

Symptoms worsen with age in all patients, primarily due to the progressive accumulation of glycolipids in tissues and blood vessel walls.

---

Complications

The clinical course of Fabry disease is variable, but typically progresses to involve multiple organs. Early signs of kidney damage include:

• Increased urine production (polyuria)
• Excessive thirst (polydipsia)
• Protein in the urine (proteinuria)

Without treatment, this progressive kidney damage typically leads to end-stage renal failure in the third or fourth decade of life.

Cardiac and neurological involvement adds further burden to the disease. The full spectrum of potential complications includes:

The progressive accumulation of glycolipids causes endothelial cell swelling and proliferation, ultimately promoting cardiovascular disease and stroke, which remain the leading causes of premature death in Fabry disease patients.

---

Diagnosis

Fabry disease should be suspected in patients who present with compatible symptoms, especially if there is a positive family history. Diagnosis is confirmed through one or both of the following approaches:

Biochemical Testing

• Measurement of alpha-galactosidase-A enzyme activity in leukocytes (white blood cells) or plasma:
  • In males: markedly reduced or absent enzyme activity is diagnostic
  • In females: enzyme activity can be in the normal range even with a GLA mutation (due to variable X-inactivation), so genetic testing is essential

Genetic Testing

• GLA gene sequencing to identify the specific pathogenic mutation. This is the gold standard for confirming a diagnosis, particularly in females, and for enabling family screening and genetic counseling.

Tissue Biopsy

Where enzyme or genetic testing is unavailable, biopsy of the skin or kidney may reveal characteristic glycolipid inclusions within cells under electron microscopy.

Newborn Screening

Fabry disease is included in newborn screening programmes in several countries, enabling early identification and treatment before organ damage occurs. Early diagnosis is critical to improving long-term outcomes.

---

Treatment

There is currently no cure for Fabry disease. Treatment is therefore aimed at relieving symptoms and preventing or delaying organ complications.

Enzyme Replacement Therapy (ERT)

The cornerstone of disease-modifying treatment is enzyme replacement therapy (ERT), in which the deficient alpha-galactosidase-A enzyme is administered intravenously every two weeks. Two approved ERT agents are available:

• Agalsidase alfa (Replagal), approved in Europe and other regions.
• Agalsidase beta (Fabrazyme), approved in the US, Europe, and worldwide

ERT reduces Gb3 accumulation and alleviates neuropathic pain while also helping preserve kidney, heart, and vascular function. This is especially true when treatment begins before significant organ damage occurs.

Chaperone Therapy

An oral therapy option is available for patients with specific amenable GLA mutations:

• Migalastat (Galafold) (Amicus Therapeutics) is a pharmacological chaperone. It works by binding to the abnormal enzyme, stabilizing it, and enhancing its residual activity. It is taken orally every other day and is approved for adults with Fabry disease who have an amenable mutation (~35–50% of known GLA variants).

Symptomatic and Supportive Treatments

Monitoring and Multidisciplinary Care

Given the multi-organ nature of Fabry disease, management requires a coordinated multidisciplinary team including:

• Metabolic/genetic specialists
• Nephrologists
• Cardiologists
• Neurologists
• Ophthalmologists
• Dermatologists

Regular monitoring of kidney function, cardiac imaging, neurological assessments, and audiological evaluations is essential to detect and address complications early.

Emerging Therapies

Research into gene therapy for Fabry disease is ongoing, with several clinical trials underway. The goal is to deliver a functional copy of the GLA gene to the patient’s cells, potentially providing a long-lasting or even curative treatment in the future.

---

Sources and Bibliography

• Fabry Disease – Syed Rizwan A. Bokhari; Hassam Zulfiqar; Anis Hariz – StatPearls, NCBI
• National Organization for Rare Disorders (NORD) – Fabry Disease
• MedlinePlus – Fabry Disease (U.S. National Library of Medicine)
• National Institute of Neurological Disorders and Stroke (NINDS) – Fabry Disease
• Galafold (migalastat) – European Medicines Agency Summary
• Osservatorio Malattie Rare – Malattia di Fabry